Navigation Links
Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results
Date:8/11/2009

on or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into, except that in particular circumstances as specifically indicated we may address the potent
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
4. Cornerstone Therapeutics Announces New Board of Directors
5. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
6. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
7. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces Management Change
10. TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform
11. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Issuance and Sale of Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The North America Phytochemicals & Plant Extracts Market ... in North America with analysis and forecast of revenue. This ... in 2012 to $930.1 million by 2018, at a CAGR ... TOC of the North America phytochemicals & plant extracts market ... It also provides a glimpse of the segmentation in the ...
(Date:7/31/2014)... The North American Colorants Market ... North America with analysis and forecast of volume ... North American Colorants Market report, to get an ... provides a glimpse of the segmentation in the ... various tables and figures. , http://www.micromarketmonitor.com/market/americas-colorants-8463333110.html ...
(Date:7/31/2014)... 2014 (HealthDay News) -- Many teens never outgrow their ... pain can persist for years, affecting teens, participation in ... left untreated, so-called growing pains can become chronic, the ... that one in three young people between the ages ... their knees," said Michael Skovdal Rathleff, a physiotherapist from ...
(Date:7/31/2014)... 2014 i2i Systems announced today it ... (SAS) to provide a robust patient referral database ... is one of the largest independent software companies in ... 40,000 patients are seen annually in its on-site HCC ... primary care, providers at the SAS HCC refer patients ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 With the brand ... a new lecture series featuring the “reality model” ... National Park, a more affordable resort pricing structure, and a ... Co-founder, says, “We have always had a great weight loss ... that differentiate Fitness Ridge. We want to change the way ...
Breaking Medicine News(10 mins):Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Phytochemicals & plant extracts (Nutraceuticals) Market is Expected to Reach $930.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Americas Colorants Market is Expected to Reach 2,006 Thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Teen 'Growing Pains' May Persist For Years 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 2Health News:SAS Selects i2i Systems for Health Care Center Patient Referral Database 3Health News:Weight Loss Destination, the Biggest Loser Resort in Utah, Rebrands as Fitness Ridge 2
... male veterans suffering from chronic obstructive pulmonary disease (COPD), ... cancer, researchers found that regular use of high dose ... cancer. ,David H. Au, M.D., M.S., of the ... along with five associates found that among 10,474 patients ...
... testosterone, which plays a key role in health and ... ,People suffering with Alzheimer's lack the ability to ... As the disease progresses, individuals may also experience changes ... agitation, as well as delusions or hallucinations. ...
... has over the years been a high source of nutrition ... that can be eaten in several forms, it is the ... With Easter just round the corner an animal rights group ... urging people not to eat eggs. ,Volunteers of ...
... fish varieties, is increasing all along the coastal regions in ... to it every year, it is estimated. // ... damage that pollution and global warming are inflicting on the ... of popular fish types, including grouper and barracuda, live near ...
... last year, has left Health Trusts short of nearly ?56million, ... from a local survey of health trusts show that almost ... money than they had expected to get under the new ... shortage, PCT may try to re allocate money from other ...
... overweight and obese individuals, the incidence of asthma increases ... weight, according to a meta-analysis of seven studies on ... first issue for April 2007 of the American Journal ... American Thoracic Society. ,E. Rand Sutherland, ...
Cached Medicine News:Health News:High Dose Inhaled Corticosteroid Use for COPD Could Cut Risk of Lung Cancer 2Health News:Global Warming Could Increase Exotic Fish Poisoning 2Health News:Asthma Incidence Shows a 50 Percent Increase in Fat People 2
(Date:7/31/2014)... WASHINGTON , July 31, 2014  CVS/pharmacy ... first pharmacy in the nation to earn the ... health care accreditation organization that establishes quality standards ... Longs Drug Store locations nationwide have earned this ... accreditation programs. Its Community Pharmacy Accreditation Program was ...
(Date:7/31/2014)... Mass., July 31, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced revenue of $70.1 million for the second quarter ... $50.8 million in revenue for the same period of ... ® Ventricular Assist Systems were sold globally compared ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
Breaking Medicine Technology:CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 2CVS/pharmacy Earns First-Ever Community Pharmacy Accreditation from URAC 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23
... International Partnership for Microbicides, issued the following statement ... and effectiveness study of BufferGel and PRO2000 (0.5 ... Microbicide Trials Network, a worldwide collaborative group funded ... released final results from its Phase II/IIb safety ...
... Only Approved Platelet Producer in Europe Represents New ... Feb. 6 Amgen (Nasdaq: AMGN ... has granted marketing authorisation for Nplate(R) (romiplostim) for ... thrombocytopenic purpura (ITP) patients who are refractory to ...
Cached Medicine Technology:New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 2New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 3New PRO2000 HIV-Prevention Findings Important Milestone on Path Toward Development of Effective Vaginal Microbicide 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 2Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 3Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 4Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 5Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 6Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 7Nplate(R) Approved in the European Union for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) 8
... The Shandon Cytospin has been ... 35 years. More than 15,000 ... reliable instrument. It provides economical ... matrix, especially hypocellular fluids such ...
... Finger Traps for optimum patient comfort. The Nylon ... with a firm grip. ISI Nylon Finger Traps ... when used with the ISI Digi Grip or ... Traps are available in non-sterile packs and come ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
Medicine Products: